SCHEMBL3210074

SCHEMBL3210074

COc1cccc(OC)c1Cc1cc2cc(Cl)ccc2nc1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
AMY1A P0DUB6 1/20 0.40
HTT P42858 1/20 0.40
DPP4 P27487 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
DHPS P49366 1/20 0.38
AURKA O14965 1/20 0.38
DAPK3 O43293 1/20 0.38
JAK2 O60674 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
PAK4 O96013 1/20 0.38
ABL1 P00519 1/20 0.38
NTRK1 P04629 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
CSF1R P07333 1/20 0.38
RET P07949 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3210319 0.92 DPP4 (0.39) TLR8SMN1; SMN2AMY1AHTTDPP4
SCHEMBL4718157 0.87 IDO1 (0.49) TLR8SMN1; SMN2DPP4ALDH1A1KDM4E
SCHEMBL3209853 0.86 TLR8 (0.42) TLR8AMY1ADHPSPDGFRBPDGFRA
SCHEMBL3218775 0.84 MAPT (0.41) TLR8SMN1; SMN2AMY1AHTTDPP4
SCHEMBL3206611 0.84 TLR8 (0.60) TLR8MEN1KMT2ADCPSNQO2
SCHEMBL3219124 0.84 KDM4E (0.47) TLR8HTTALDH1A1KDM4EPDGFRB
SCHEMBL3215535 0.82 DPP4 (0.39) TLR8SMN1; SMN2AMY1AHTTDPP4
SCHEMBL3222731 0.81 PDE10A (0.46) TLR8ALDH1A1LRRK2CSNK1D
SCHEMBL3217299 0.81 TLR8 (0.54) TLR8MEN1KMT2AHSP90AA1HSP90AB1
SCHEMBL3197519 0.80 TLR8 (0.40) TLR8AMY1APDGFRBPDGFRAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221371-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-08-07 US disclosed
US-20100041698-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-02-18 US disclosed
EP-1917245-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS Abbott GmbH & Co. KG (DE) 2008-05-07 EP disclosed
WO-2007022946-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS ABBOTT GMBH & CO. KG (DE) 2007-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221371-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS HTR5A, HTR1A, HTR2C TLR8 3013/4885SMN1; SMN2 1722/4885AMY1A 4292/4885
US-20100041698-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS HTR5A, HTR1A, HTR2C TLR8 3013/4885SMN1; SMN2 1722/4885AMY1A 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.